Cingulate Inc. (NASDAQ:CINGW) Short Interest Down 74.1% in August

Cingulate Inc. (NASDAQ:CINGW) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 1,533 shares, a drop of 74.1% from the August 15th total of 5,920 shares. Based on an average trading volume of 13,979 shares, the short-interest ratio is presently 0.1 days.

Cingulate Stock Performance

Shares of Cingulate stock traded down $0.00 during trading on Friday, reaching $0.01. The company’s stock had a trading volume of 900 shares, compared to its average volume of 32,804. The company has a 50-day moving average price of $0.01 and a two-hundred day moving average price of $0.02. Cingulate has a fifty-two week low of $0.00 and a fifty-two week high of $0.12.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.